<?xml version="1.0" encoding="UTF-8"?>
<p id="p0280">Fluphenazine also possesses antiviral activity towards MERS-CoV and SARS-CoV (
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>; 
 <xref rid="bib46" ref-type="bibr">Pillaiyar et al., 2020</xref>), which also suggests potential inhibitor activities for viruses using the clathrin-mediated endocytosis. The drug inhibits also HCV (
 <xref rid="bib6" ref-type="bibr">Chamoun-Emanuelli et al., 2013</xref>; 
 <xref rid="bib12" ref-type="bibr">Dyall et al., 2017</xref>) and EBOV (
 <xref rid="bib34" ref-type="bibr">Johansen et al., 2015</xref>) entry into the host cells. Based on the EC
 <sub>50</sub> values obtained by 
 <xref rid="bib11" ref-type="bibr">Dyall et al. (2014)</xref> chlorpromazine is more efficient towards SARS-CoV than fluphenazine, while fluphenazine is more potent against MERS-CoV than chlorpromazine (
 <xref rid="bib11" ref-type="bibr">Dyall et al., 2014</xref>). Moreover, the drug inhibits MERS-CoV replication and cell-cell fusion. The IC
 <sub>50</sub> values of the analyzed drugs inhibiting cell-cell fusion and clathrin-mediated endocytosis were shown in 
 <xref rid="tbl1" ref-type="table">Table 1</xref>. Interestingly, a comparison of the IC
 <sub>50</sub> values for MERS-CoV replication and cell-cell fusion and clathrin-mediated endocytosis obtained by 
 <xref rid="bib40" ref-type="bibr">Liu et al. (2015)</xref> and 
 <xref rid="bib11" ref-type="bibr">Dyall et al. (2014)</xref> show that in all cases fluphenazine is more effective than chlorpromazine.
</p>
